A61K 31/4748
Forming part of bridged ring systems
Official title: forming part of bridged ring systems (strychnine A61K31/475; morphinan derivatives A61K31/485)
A61K31/4748 (Forming part of bridged ring systems) appears on 236 US grants and 461 published applications in this corpus.
Search patents in A61K- Granted patents
- 236
- Published applications
- 461
- Assignees
- 189
- Inventors
- 614
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 3 |
| 2002 | 5 | 5 |
| 2003 | 3 | 5 |
| 2004 | 2 | 2 |
| 2005 | 0 | 3 |
| 2006 | 0 | 3 |
| 2007 | 0 | 5 |
| 2008 | 0 | 7 |
| 2009 | 0 | 6 |
| 2010 | 3 | 6 |
| 2011 | 3 | 9 |
| 2012 | 2 | 5 |
| 2013 | 8 | 28 |
| 2014 | 12 | 27 |
| 2015 | 13 | 42 |
| 2016 | 28 | 47 |
| 2017 | 23 | 34 |
| 2018 | 24 | 24 |
| 2019 | 17 | 32 |
| 2020 | 16 | 33 |
| 2021 | 14 | 40 |
| 2022 | 13 | 20 |
| 2023 | 11 | 19 |
| 2024 | 15 | 28 |
| 2025 | 11 | 14 |
| 2026 | 6 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain29 Sep 2026US 12,746,235 B2Biobina LLC
- Abuse-resistant pharmaceutical composition for the treatment of opioid dependence11 Aug 2026US 12,702,666 B2Edenbridge Pharmaceuticals, LLC
- Method for increasing the lifespan and motility of animal sperm using an inhibitor of Slo3 potassium channel19 May 2026US 12,628,817 B2Centre National de la Recherche Scientifique (CNRS)
- Systems and methods for treating an opioid-induced adverse pharmacodynamic response24 Mar 2026US 12,582,647 B2Purdue Pharma L. P.
- Compositions for improving brain health and memory13 Jan 2026US 12,521,365 B2CytoSolve, Inc.
- Ingestible formulations comprising methylliberine and one or more sugars and their use to treat the adverse effects of alcohol consumption1 Oct 2026US 2026/0294917 A1Lucid Psycheceuticals Inc.
- Transdermal therapeutic system for the transdermal administration of huperzine a13 Aug 2026US 2026/0232605 A1
- Novel compounds and uses thereof13 Aug 2026US 2026/0234163 A1Acelink Therapeutics, Inc.
- Combination therapies for treatment of hearing disorders23 Jul 2026US 2026/0207616 A1Gateway Biotechnology, Inc.
- Pyridine polycyclic compound inhibitor, preparation method therefor and use thereof16 Jul 2026US 2026/0200931 A1Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Most cited
By later US patents
- Immune response modifier compounds for treatment of TH2 mediated and related diseases285US 6,039,969 A3M Innovative Properties Company · 2000
- Formulations and methods for treatment of mucosal associated conditions with an immune response modifier193US 6,486,168 B13M Innovative Properties Company · 2002
- Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan160US 9,238,032 B2Antecip Bioventures II LLC · 2016
- Bupropion as a modulator of drug activity158US 9,168,234 B2Antecip Bioventures II LLC · 2015
- Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects158US 9,198,905 B2Antecip Bioventures II LLC · 2015